blue-male-back-home.jpg

SCIENCE-DRIVEN,

HUMAN-CENTERED

Harnessing the power of interleukin-10,
master anti-inflammatory cytokine

ribbon-3.jpg

OUR UNIQUE APPROACH

Over 300 million people worldwide suffer from chronic inflammatory diseases. There is a large unmet need for treatments for chronic inflammatory disease that are efficacious and safe. Xalud Therapeutics is developing a non-viral gene therapy targeting immune modulation. Our mission is to harness the power of interleukin-10 (IL-10), a potent anti-inflammatory cytokine, to address the root cause of inflammation and subsequently restore homeostasis in the immune system.

xalud-male-f.jpg

AN UPSTREAM TREATMENT FOR
CHRONIC INFLAMMATION THAT
RESTORES BALANCE TO THE

IMMUNE SYSTEM

 
 

OUR SCIENCE

A healthy, strong body lives in a state of equilibrium. Every day, it detects potential signals of injury or chronic disease progression and naturally restores itself by finely balancing anti-inflammatory cytokines and pro-inflammatory mediators. Unfortunately when the body's immune system is unbalanced, inflammation can flare and persist over long periods of time. This results in a myriad of diseases and associated symptoms, including chronic, debilitating pain that prevents millions of people from living healthy productive lives.

Xalud Therapeutics aims to break this cycle of chronic, pathologic inflammation. Instead of masking symptoms like traditional pain drugs, we help the body to restore the critical balance of inflammatory and restorative pathways by adding back one of the body's own natural defenses to increase important anti-inflammatory signals.

OUR PLATFORM

IL-10 is a potent anti-inflammatory cytokine that inhibits and
counterbalances the effects of inflammatory cytokines. Insufficient IL-10 expression or signaling have been implicated in inflammation and numerous immune disease states. Our breakthrough lead therapeutic candidate, XT-150, combats pathologic inflammation locally through expression of IL-10v, a proprietary modified variant of IL-10. Xalud is currently evaluating XT- 150 across multiple treatment indications in preclinical and clinical studies.

white-spine2.jpg
 
pipeline-mobile2.png
blue-male-back1.jpg

OUR PIPELINE

 
may-pipeline-mobile.png

MUSCULOSKELETAL


Osteoarthritis

 

Facet Syndrome

 

Degenerative Disc Disease

 

CNS

 

Peripheral Neuropathic Pain - Lumbar Radiculopathy


Central Neuropathic Pain

 

Multiple Sclerosis


OTHER TARGETS


Ophthalmic, Gastrointestinal, Dermal

PRE-CLINICAL

PHASE 1/2

PHASE 2/3

IND-ENABLING

blue-hand.jpg

OUR LEADERSHIP

 
Headshots_diem.jpg

DIEM NGUYEN, Ph.D., MBA

Chief Executive Officer

Bio

Headshots_howard.jpg

HOWARD RUTMAN, M.D., MBA

Chief Development Officer

Bio

Headshots_steve.jpg

STEVE COLLINS, M.D., Ph.D.

Chief Medical Officer

Bio

Headshots_Brendan2.jpg

BRENDAN O’LEARY, CFA

Chief Operating Officer

Bio

Headshots_Kristin.jpg

KRISTIN MURRAY

Chief Regulatory Officer

Bio

Headshots_Steve-Vicik.jpg

STEVE VICIK, Ph.D.

Chief Technology Officer

Bio

Headshots_Ray.jpg

RAY CHAVEZ, Ph.D.

R&D Lead

Bio

Headshots_Kristen.jpg

KRISTEN ALBRIGHT

Commercial Development Lead

Bio

PBM CAPITAL

PAUL B. MANNING

Bio

SEAN STALFORT

Bio

JAYSON RIEGER

Bio

SUNG YOU

Bio

ADVISORS

John Forsayeth, PhD     Linda Watkins, PhD     Tarek Samad, PhD

Lee Simon, MD, FACP FACR      Nathaniel Katz, MD      Eric Grigsby, MD      Leonardo Kapural, MD

News: Xalud Therapeutics Expands Leadership Team with Key Appointments

xalud-male-back3.jpg

JOIN XALUD

At Xalud, we seek to address the significant unmet need for safe and efficient treatments for chronic pain-related diseases. Join us.